Company: CNTB
Filing Date: 2025-09-10
Form Type: POS AM
Source: 0001193125-25-200186
Chunk: 64

Company: Connect Biopharma Holdings Ltd
Filing Date: 2025-09-10
Form: POS AM
Chunk 64
---
, China 215400, and its telephone number is +86 512 5357 7866. Our website address is www.connectbiopharma.com. The information contained on, or accessible through, our website does not constitute a part of this prospectus. We have included our website address in this prospectus solely as an inactive textual reference. The SEC maintains an Internet site that contains reports, proxy and information statements, and other information regarding issuers that file electronically with the SEC at www.sec.gov. Risk Factor Summary Investing in our securities involves a high degree of risk. Below is a summary of certain factors that make an investment in our securities speculative or risky. Importantly, this summary does not address all of the risks that we face. Additional discussion of the risks summarized below, as well as other risks that we face, can be found under the heading “Risk Factors” contained in the applicable prospectus supplement and in any free writing prospectuses we have authorized for use in connection with a specific offering, and under similar headings in the documents that are incorporated by reference into this prospectus. Risks Related to Our Limited Operating History, Financial Position and Capital Requirements

| • |     | We have a limited operating history, have incurred significant operating losses since our inception and expect                                                                                 
 to incur significant losses for the foreseeable future. We might never generate any additional revenue or become profitable or, if we achieve profitability, we might be unable to sustain it. |

| • |     | We will require substantial additional capital to achieve our goals, and a failure to obtain or access this                                                                                                                                              
 necessary capital when needed on acceptable terms, or at all, could force us to delay, limit, reduce or terminate our product development programs, commercialization efforts or other operations. Our existing capital will not be sufficient for us to 
 fund rademikibart (formerly CBP-201) or any other future product candidates (collectively, our “Product Candidates”) through regulatory approvals, and we will need additional capital to complete                                                       
 their development and commercialization.                                                                                                                                                                                                                 |

3

| • |     | Raising additional capital may cause substantial dilution to our shareholders, including holders of our                
 Ordinary Shares, restrict our operations or require us to relinquish rights to our technologies or Product Candidates. |

Risks Related to the Discovery, Development and Regulatory Approval of Our Product Candidates

| • |     | Clinical drug development involves a lengthy and expensive process, with an uncertain outcome. We may incur                                                
 unforeseen costs or experience delays in completing